General Biotechnologies sources and develops undervalued discoveries in the life sciences from academic technology transfer offices. Their flagship program is Nivien Therapeutics, an oncology therapeutics company based on research from Harvard Medical School's Systems Biology Department. Nivien targets a biological mechanism that enables cancer cells to inactivate or export chemotherapy and immunotherapy drugs, with positive animal data in pancreatic cancer models. The company was co-founded by Nathaniel Brooks Horwitz, Harvard A.B. 2018 in molecular and cellular biology, and Nikita Shah, Harvard A.B. 2017 in human development and regenerative biology. Marc Kirschner of Harvard Medical School serves as chair of the scientific advisory board for Nivien. Nivien Therapeutics maintains a lab at the IndieBio Accelerator in San Francisco.